Subclinical atherosclerosis in patients with relapsing-remitting multiple sclerosis

被引:6
|
作者
Omerzu, Tomaz [1 ]
Magdic, Jozef [1 ]
Hojs, Radovan [2 ,3 ]
Potocnik, Uros [2 ]
Gorenjak, Mario [2 ]
Fabjan, Tanja Hojs [1 ,2 ]
机构
[1] Univ Med Ctr Maribor, Dept Neurol, Ljubljanska 5, Maribor 2000, Slovenia
[2] Univ Maribor, Fac Med, Taborska Ulica 8, Maribor 2000, Slovenia
[3] Univ Med Ctr Maribor, Dept Nephrol, Clin Internal Med, Ljubljanska 5, Maribor 2000, Slovenia
关键词
Inflammation; Neuroimmunology; Carotid intima media thickness; Cystatin C; Interleukin  6; CAROTID-ARTERY ATHEROSCLEROSIS; DISABILITY PROGRESSION; FUNCTIONAL COMPOSITE; INFLAMMATION; DISEASE; RISK; COMORBIDITY; DIALYSIS; COMMON;
D O I
10.1007/s00508-021-01862-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Multiple sclerosis is an inflammatory disorder of the central nervous system. Inflammation may create high susceptibility to subclinical atherosclerosis. The purpose of this study was to compare subclinical atherosclerosis and the role of inflammatory cytokines between the group of patients with relapsing-remitting multiple sclerosis (RRMS) and healthy controls matched for age and sex. Methods The study group consisted of 112 non-diabetic and non-hypertensive RRMS patients treated with disease modifying drugs (DMD) and the control group was composed of 51 healthy subjects. The common carotid artery (CCA) intima media thickness (IMT) was investigated. Serum levels of risk factors for atherosclerosis and inflammatory cytokines were also determined. Results The mean CCA IMT (0.572 +/- 0.131 mm vs. 0.571 +/- 0.114 mm) did not differ (p > 0.05) between patients and controls. The RRMS patients' CCA IMT was significantly correlated with serum interleukin 6 (IL-6) (p = 0.027), high-sensitivity C-reactive protein (hs-CRP) (p = 0.027), cystatin C (p < 0.0005), glucose (p = 0.031), cholesterol (p = 0.008), LDL (p = 0.021), erythrocyte sedimentation rate (p = 0.001) and triglyceride (p = 0.018) level. We fitted generalized linear models in order to assess the relationship between CCA IMT and IL-6 with adjustment for sex and age. The obtained results showed that adjusted for age (p < 0.001) and sex (p = 0.048) IL-6 serum levels statistically significantly (p = 0.009) predict CCA IMT only in the RRMS group. Conclusion The findings of the present study suggest that when treated with DMD RRMS might not be an independent risk factor for early atherosclerosis presenting with arterial wall thickening; however, the results suggest a significant association of IL-6 serum levels with CCA IMT only in the RRMS group.
引用
收藏
页码:40 / 47
页数:8
相关论文
共 50 条
  • [41] Predicting response to fingolimod in patients with relapsing-remitting multiple sclerosis
    Giuliani, M.
    Prosperini, L.
    Fanelli, F.
    Hirsch, M. N.
    De Angelis, F.
    Pozzilli, C.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 306 - 306
  • [42] Natalizumab reduces apathy in relapsing-remitting multiple sclerosis patients
    Berkovich, R.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S154 - S155
  • [43] Autoimmunity in patients treated with alemtuzumab for relapsing-remitting multiple sclerosis
    Fox, E. J.
    Arnold, D. L.
    Cohen, J.
    Coles, A. J.
    Confavreux, C.
    Hartung, H. -P.
    Havrdova, E.
    Selmaj, K.
    Weiner, H.
    Lake, S. L.
    Margolin, D. H.
    Oyuela, P.
    Panzara, M.
    Compston, D. A. S.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 465 - 466
  • [44] Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis
    Cocco, E.
    Marchi, P.
    Sardu, C.
    Russo, P.
    Paolillo, A.
    Mascia, M. G.
    Solla, M.
    Frau, J.
    Lorefice, L.
    Massole, S.
    Floris, G.
    Marrosu, M. G.
    MULTIPLE SCLEROSIS JOURNAL, 2007, 13 (08) : 975 - 980
  • [45] Cytotoxic B Cells in Relapsing-Remitting Multiple Sclerosis Patients
    Boldrini, Vinicius O.
    Marques, Ana M.
    Quintiliano, Raphael P. S.
    Moraes, Adriel S.
    Stella, Carla R. A. V.
    Longhini, Ana Leda F.
    Santos, Irene
    Andrade, Marilia
    Ferrari, Breno
    Damasceno, Alfredo
    Carneiro, Rafael P. D.
    Brandao, Carlos Otavio
    Farias, Alessandro S.
    Santos, Leonilda M. B.
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [46] Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis
    Arnal-Garcia, Carmen
    Rosa Garcia-Montero, Ma
    Malaga, Ignacio
    Millan-Pascual, Jorge
    Oliva-Nacarino, Pedro
    Ramio-Torrenta, Lluis
    Oreja-Guevara, Celia
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2013, 17 (01) : 50 - 54
  • [47] Cognitive deterioration in patients with initial relapsing-remitting multiple sclerosis
    Genov, K.
    Dimitrova, M.
    JOURNAL OF NEUROLOGY, 2012, 259 : S195 - S196
  • [48] Sexual dysfunction in female patients with relapsing-remitting multiple sclerosis
    Bartnik, Pawel
    Wielgos, Aleksandra
    Kacperczyk, Joanna
    Pisarz, Katarzyna
    Szymusik, Iwona
    Podlecka-Pietowska, Aleksandra
    Zakrzewska-Pniewska, Beata
    Wielgos, Miroslaw
    BRAIN AND BEHAVIOR, 2017, 7 (06):
  • [49] Circuit class therapy in patients with relapsing-remitting multiple sclerosis
    Kolcava, J.
    Kocica, J.
    Musilova, M.
    Dosbaba, F.
    Kratochvilova, J.
    Krizova, D.
    Stourac, P.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 633 - 634
  • [50] Clinical experience with cladribine in patients with relapsing-remitting multiple sclerosis
    Hodgkinson, S.
    Lizak, N.
    Butler, E.
    Lechner-Scott, J.
    Slee, M.
    McCombe, P.
    Shaw, C.
    Skibina, O.
    Vucic, S.
    Shuey, N.
    Barnett, M.
    Parratt, J.
    Butzkueven, H.
    Jack, D.
    Fabris, J.
    Kalincik, T.
    Jokubaitis, V. G.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (09) : NP64 - NP65